The development of biologic end points in patients treated with differentiation agents: An experience of retinoids in prostate cancer

Clinical Cancer Research

Volumn 6, Issue 3, 2000, Pages 838-846

  Kelly, W Kevin ^a,b   Osman, Iman ^a   Reuter, Victor E ^a   Curley, Tracy ^a   Heston, Warren D W ^a   Nanus, David M ^b   Scher, Howard I ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; ISOTRETINOIN; KI 67 ANTIGEN; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; RETINOIC ACID;

ADULT; AGED; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CELL PROLIFERATION; CHEILITIS; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FATIGUE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL; PROSTATE CARCINOMA; TREATMENT OUTCOME;

AGED; ANTIGENS, SURFACE; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOPSY; BONE NEOPLASMS; CARBOXYPEPTIDASES; CHEILITIS; DYSPNEA; EXANTHEMA; FATIGUE; GLUTAMATE CARBOXYPEPTIDASE II; HEMATOLOGIC DISEASES; HUMANS; INTERFERON ALFA-2A; KI-67 ANTIGEN; LIVER; MALE; MIDDLE AGED; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TRANSAMINASES; TREATMENT OUTCOME; TRETINOIN;

EID: 0034103154     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Greco, K. E., and Kulawiak, L. Prostate cancer prevention: risk reduction through life-style, diet and chemoprevention. Oncology Nursing Forum, 21: 1504-1511, 1994.
2. Pienta, K. J., and Esper, P. S. Risk factors for prostate cancer. Ann. Intern. Med., 118: 793-803, 1993.
3. Pollard, M., Luckert, P. H., and Sporn, M. B. Prevention of primary prostate cancer in Lobund-Wistar rats by N-(4-hydroxyphenyl)retinamide. Cancer Res., 51: 3610-3611, 1991.
4. Trump, D. Retinoids in bladder, testis and prostate cancer: epidemiologic, pre-clinical and clinical observations., Leukemia (Baltimore), 3: S50-S54, 1994.
5. DiPaola, R. S., Weiss, R. E., Cummings, K. B., Kong, F. M., Jirtle, R. L., Anscher, M., Gallo, J., Goodin, S., Thompson, S., Rasheed, Z., Aisner, J., and Todd, M. Effect of 13-cis-retinoic acid and α interferon on transforming growth factor B1 in patients with a rising prostate specific antigen. Clin. Cancer Res., 3: 1999-2004, 1997.
6. Scher, H. I., Mazumdar, M., and Kelly, W. K. Clinical trials in relapsed prostate cancer: defining the target. J. Natl. Cancer Inst., 88: 1623-1634, 1996.
7. Scher, H. I., Zhang, Z. F., and Kelly, W. K. Hormone and antihormone withdrawal therapy: implications for management of androgen independent prostate cancer. Urology, 47: 61-69, 1996.
8. Muindi, J. R. F., Young, C. W., and Warrell, R. P. Clinical pharmacology of all-trans retinoic acid. Leukemia (Baltimore), 8: S16-S21, 1994.
9. Rigas, J. R., Francis, P. A., Muindi, J. R. F., Kris, M. G., Huselton, C., DeGrazia, F., Orazem, J. P., Young, C. W., and Warrell, R. P. Constitutive variability in the pharmacokinetics of the natural retinoid, all-trans retinoic acid and its modulation by ketoconazole. J. Natl. Cancer Inst., 85: 1921-1926, 1997.
10. Smith, M., Parkison, D. R., Cheson, B. D., and Freidman, M. A. Retinoids in cancer. J. Clin. Oncol., 10: 839-864, 1992.
11. Eisenhauer, E. A., Lippman, S., Kavanagh, J. J., Parades-Espinoza, M., Arnold, A., Hong, W. K., Massimini, G., Schleuniger, U., Bollag, W., Holdener, E. E., and Krakoff, I. Combination 13-cis-retinoic acid and interferon α-2a in the therapy of solid tumors. Leukemia (Baltimore), 8: 38-41, 1994.
12. Gavrieli, Y., Sherman, Y., and Ben-Sasson, S. A. Identification of programmed cell death in situ via specific labelling of nuclear DNA fragmentation. J. Cell Biol., 119: 493-501, 1992.
13. Kelly, W. K., Curley, T., Leibettz, C., Dnistrian, A., Schwartz, M., and Scher, H. I. Prospective evaluation of hydrocortisone and suramin. J. Clin. Oncol., 13: 2208-2213, 1995.
14. Chang, S. S., Reuter, V. E., Heston, W. D. W., Hutchinson, B., Grauer, L. S., and Gaudin, P. B. Short term neoadjuvant androgen deprivation does not affect prostate specific membrane antigen (PSMA) expression in prostate tissue. Cancer (Phila.), 88: 407-415, 2000.
15. Heston, W. D. W. Characterization and glutamyl preferring carboxypeptidase function of prostate specific membrane antigen: a novel folate hydrolase. Urology, 15 (Suppl. 3a): 104-112, 1997.
16. Kawakami, M., and Nakayama, J. Enhanced expression of prostate-specific membrane antigen gene in prostate cancer as revealed by in situ hybridization. Cancer Res., 57: 2321-2324, 1997.
17. Bostwick, D. G., Pacelli, A., Blute, M., Roche, P., and Murphy, G. P. Prostate specific membrane antigen expression in prostate intra-epithelial neoplasia and adenocarcinoma. Cancer (Phila.), 82: 2256-2261, 1998.
18. Silver, D. A., Pellicer, I., Fair, W. R., Heston, W. D. W., and Cordon-Cardo, C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin. Cancer Res., 3: 81-86, 1997.
19. Kelly, W. K., Slovin, S. F., and Scher, H. I. Steroid hormone withdrawal syndrome. In: J. E. Oesterling (ed.), Prostate Specific Antigen: The Best Prostatic Tumor Marker, Vol. 24, pp. 421-431. Philadelphia: W. B. Saunders Co., 1997.
20. Jutley, J. K., Reaney, S., Kelleher, J., and Whelan, P. Interactions of retinoic acid and androgens in human prostatic tissue. Prostate, 16: 299-304, 1990.